Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

ipilimumab

Known as: MOAB-CTLA-4, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, monoclonal antibody CTLA-4 
A recombinant human immunoglobulin (Ig) G1 monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
BACKGROUND In the ongoing phase 3 CheckMate 214 trial, nivolumab plus ipilimumab showed superior efficacy over sunitinib in… Expand
Is this relevant?
Review
2019
Review
2019
  • Anand Rotte
  • Journal of experimental & clinical cancer…
  • 2019
  • Corpus ID: 189817689
Targeting checkpoints of immune cell activation has been demonstrated to be the most effective approach for activation of anti… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
  • table 4
Is this relevant?
Review
2019
Review
2019
Following initial successes in melanoma treatment, immunotherapy has rapidly become established as a major treatment modality for… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Is this relevant?
Review
2019
Review
2019
Objective Insulin-dependent diabetes can occur with immune checkpoint inhibitor (ICI) therapy. We aimed to characterize the… Expand
Is this relevant?
Review
2019
Review
2019
Monoclonal antibodies targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4), programed cell death 1 (PD-1), or its ligand (PD-L1… Expand
Is this relevant?
Review
2019
Review
2019
BACKGROUND There is no recommended therapy for malignant pleural mesothelioma that has progressed after first-line pemetrexed and… Expand
Is this relevant?
Review
2018
Review
2018
Abstract Objective To provide a complete toxicity profile, toxicity spectrum, and a safety ranking of immune checkpoint inhibitor… Expand
Is this relevant?
Review
2018
Review
2018
Importance Immune checkpoint inhibitors (ICIs) are now a mainstay of cancer treatment. Although rare, fulminant and fatal toxic… Expand
  • table 1
  • figure 2
  • table 2
Is this relevant?
Review
2017
Review
2017
PurposeEvaluation of response to immunotherapy is a matter of debate. The aim of the present study was to evaluate the response… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
Review
2017
Review
2017
The purpose of this study was to evaluate 18F-FDG PET/CT scanning as an early predictor of response to immune checkpoint… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 2
Is this relevant?